Despite the widespread popularity of new weight-loss medications, research suggests a non-drug alternative is significantly ...

On December  15, 2025, UBS reaffirmed its Neutral (Hold) rating on NVO with an unchanged price target of DKK 295, reflecting ...

U.S. drug maker Eli Lilly & Co. is slashing the prices of its popular diabetes and weight-loss drugs Mounjaro and Zepbound by ...

Geneticist Michael Klotsman was frustrated by human drug development. That led him to launch a startup focused on treatments ...

Judges allow consolidation of vision loss lawsuits filed against Novo Nordisk and Eli Lilly over diabetes and weight loss ...

GLP-1 weight loss drugs are proving beneficial for people struggling with obesity and diabetes, but there is another surprising side effect coming to light.

Explore Pfizer Inc.’s 2025-2026 outlook: challenges, flat revenues, patent risks, and potential from the Metsera deal. Click ...

The U.S. pharmaceutical industry in 2025 remains one of the nation’s most dynamic and profitable economic sectors.

Semaglutide can help the body make more insulin and improves insulin sensitivity, which in turn lowers blood-glucose levels ...